VFA
ATRS

Virtus Fund Advisers’s Antares Pharma, Inc. ATRS Stock Holding History

Virtus Fund Advisers’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-9,961
Closed -$27K – 2131
2014
Q2 		$27K Buy
+9,961
New +$30K ﹤0.01% 2271

Other funds holding ATRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WHI
William Harris Investors Chicago, Illinois $347M AUM 3.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Virtus Fund Advisers's ATRS Position: Q3 2014 in Review

Virtus Fund Advisers sold out of Antares Pharma, Inc. (ATRS) in Q3 2014, closing a stake of 9,961 shares — an estimated $27K sold.

Virtus Fund Advisers first reported a position in ATRS in Q2 2014 and held it in 1 quarter. The position peaked at $27K in Q2 2014. 82 funds tracked by Wall St. Rank hold ATRS as of Q3 2014.

  • Virtus Fund Advisers reported no remaining Antares Pharma, Inc. position as of Q3 2014 after selling out during the quarter.
  • Virtus Fund Advisers sold 9,961 Antares Pharma, Inc. shares in Q3 2014, an estimated $27K.
  • Virtus Fund Advisers first reported a position in Antares Pharma, Inc. in Q2 2014 and held it in 1 quarter.
  • Virtus Fund Advisers's Antares Pharma, Inc. position peaked at $27K in Q2 2014.
  • 82 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q3 2014.

Based on Virtus Fund Advisers's 13F filing for Q3 2014, filed 31 Oct 2014.